Net loss was $1.7 M or $0.02 per share Read more…
Positive Results from in vivo Animal Study of Parkinson’s disease Read more…
Cell and tissue therapy, “My a__” Read more…
A net loss of $2.47M or $0.03 per share Read more…
To modify human stem cells by using engineered proteins, called “transducible transcription factors” or “TTFs.” Read more…
Net loss of $4.1M or $0.05 per share Read more…
OTCBB: ISCO has completed a financing and also changed the composition of its Board of Directors Read more…
A Q3/11 net loss of $2.672M or $0.03 per share. Read more…
Dr. Andrey Semechkin is new Co-Chairman and Kurt May is President and COO Read more…
Research has established that the brand’s proprietary stem cell technology is a critical point of difference <in the skin care market>, Read more…
Founder and Director of Research, Henry McCusker enters his tenth (10) year at Scimitar Equity with past experience in sell-side analysis, buy-side management, corporate management and due diligence.